Baird Medical Swings to Profitability: H1 2026 Revenue Up 25% to $9.9M, Net Income Positive
BDMD sits 51% above its 52-week low of $0.757 on light trading volume (0.2× avg).
Summary
Baird Medical reported H1 2026 revenue of $9.9 million (+24.6% YoY) and its first positive net income of $14,000, driven by U.S. expansion and cost cuts, though cash remains critically low at $289,000.
Key Events · Earnings and Guidance · BDMD
-
First Profitable Half-Year
Net income of $14,000 for H1 2026 versus a net loss of $11.4 million in H1 2025, marking the company's first positive net income period.
-
Revenue Up 25% to $9.9M
Revenue grew 24.6% year-over-year to $9.9 million, with approximately two-thirds generated outside the PRC and U.S. revenue rising to ~27% of total from under 2%.
-
Gross Margin Expands to 87%
Gross profit increased 32% to $8.6 million, with gross margin improving to 87.0% from 82.1% due to geographic and product mix shifts.
-
Operating Expenses Cut 54%
Total operating expenses fell to $7.8 million from $17.0 million, driven by reductions in R&D ($1.4M vs $7.2M) and G&A ($3.4M vs $8.7M), partially offset by higher selling and marketing costs.
Analysis · BDMD · Industrial Applications And Services
Baird Medical delivered its first profitable half-year since going public, with revenue up 24.6% to $9.9 million and net income of $14,000 versus an $11.4 million loss a year earlier. The turnaround was driven by a 32% jump in gross profit to $8.6 million (87% margin) and a 54% cut in operating expenses to $7.8 million, as R&D and G&A spending fell sharply. U.S. revenue now accounts for roughly 27% of total sales, up from under 2% a year ago, validating the company's international expansion strategy. However, the balance sheet remains fragile: cash is just $289,000 against $10.8 million in short-term loans and $30.7 million in accounts receivable, most of which was previously disclosed as overdue. The results are preliminary and unaudited, subject to year-end adjustments.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 29.9% of the 1988 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDMD was trading at $1.14 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $47.3M. The 52-week trading range was $0.76 to $3.70. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.